Lexaria Bioscience (LEXX) Free Cash Flow (2010 - 2026)

Lexaria Bioscience has reported Free Cash Flow for 17 years, with the latest figure at -$1.6 million in Q2 2026.

• Quarterly Free Cash Flow rose 54.38% year-over-year to -$1.6 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$7.5 million (up 23.56% YoY) and the FY2025 annual result came in at -$10.5 million, down 109.42% from the prior year.
• Free Cash Flow advanced to -$1.6 million in Q2 2026 per LEXX's latest filing, from -$2.2 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$619614.0 in Q1 2024 and troughed at -$3.6 million in Q2 2025.
• A 5-year average of -$1.7 million and a median of -$1.4 million in 2022 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 64.22% in 2025, down 183.08% in 2025.
• Over 5 years, Free Cash Flow stood at -$1.3 million in 2022, then increased by 6.65% to -$1.2 million in 2023, then tumbled by 132.78% to -$2.8 million in 2024, then jumped by 64.22% to -$984098.0 in 2025, then slumped by 66.14% to -$1.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$1.6 million, -$2.2 million, and -$984098.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.